Aker BioMarine ASA Stocks

NOK 108Last Updated 10.04.2026

Issuer Rating

3/7
Performance

Modest

Risk

Moderate

Recommendation

Sell

Market Cap

NOK 986.82M

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
NOK 108
Key Takeaways

Risk factor

Considerable default risk

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Aker BioMarine AS develops, produces, and sells krill-derived ingredients for nutraceutical, dietary supplement, and animal feed applications in Norway, the Americas, the Asia Pacific, Europe, the Middle East, and Africa. It operates through two segments, Ingredients and Brands. It provides Superba, a krill-based ingredients for nutraceutical, including phospholipid complex of choline, omega-3s, and antioxidant astaxanthin; QRILL Aqua, a krill-based ingredients for aquaculture; and QRILL Pet, a krill-based ingredients animal feed application. The company also offers LYSOVETA, a delivery platform based on LPC-bound EPA and DHA from krill; and INVI, a hydrolyzed protein isolate for food and beverage applications. In addition, it distributes human health and nutrition products, and natural supplements, as well as provides AION, a circular solution provider that recycles waste and re-use materials. The company was founded in 2006 and is headquartered in Lysaker, Norway. Aker BioMarine ASA is a subsidiary of Aker ASA.

Company Valuation

Greatly overvalued
1/7

Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBI

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Neutral
4/7

The average target price of AKBM.OL is 122 and suggests 13% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendatio

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks